一名早期乳腺癌患者在接受多西他赛治疗后出现严重肌痛，随后因产气荚膜梭菌引发暴发性感染性休克。
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment.
作者信息
Minisini Alessandro Marco, Menis Jessica, Follador Alessandro, Avellini Claudio, Fasola Gianpiero
机构信息
Department of Oncology and.
Department of Pathology, University and General Hospital of Udine, Italy.
出版信息
Clin Pract. 2011 May 12;1(2):e33. doi: 10.4081/cp.2011.e33. eCollection 2011 May 16.
Abstract
Anaerobic bacteraemia could be a life-threatening condition in neutropenic patients receiving chemotherapy. Taxane therapy is associated with necrotising inflammation of the caecum (named also typhlitis) that could be a potential source for bacteraemia. We report the case of a sudden onset of septic shock by Clostridium perfringens in a young patient treated with docetaxel as adjuvant chemotherapy for early breast cancer. A mini-review of the literature has been performed.
摘要
厌氧菌血症对于接受化疗的中性粒细胞减少患者而言可能是一种危及生命的病症。紫杉烷疗法与盲肠坏死性炎症（也称为盲肠炎）相关，而盲肠炎可能是菌血症的一个潜在来源。我们报告了一例年轻患者的病例，该患者在接受多西他赛辅助化疗治疗早期乳腺癌时突然发生产气荚膜梭菌所致的感染性休克。我们还对相关文献进行了简要综述。
相似文献
1
Fulminating septic shock from Clostridium perfringens in an early breast cancer patient with severe myalgia after docetaxel treatment.
Clin Pract. 2011 May 12;1(2):e33. doi: 10.4081/cp.2011.e33. eCollection 2011 May 16.
2
Fulminant septic shock due to Clostridium perfringens skin and soft tissue infection eight years after liver transplantation.
Ann Transplant. 2011 Jul-Sep;16(3):143-6. doi: 10.12659/aot.882009.
3
Taxanes for the adjuvant treatment of early breast cancer: systematic review and economic evaluation.
Health Technol Assess. 2007 Oct;11(40):1-144. doi: 10.3310/hta11400.
4
Colitis associated with docetaxel-based chemotherapy in patients with metastatic breast cancer.
Lancet. 2000 Jan 22;355(9200):281-3. doi: 10.1016/S0140-6736(99)06195-4.
5
Neutropenic Enterocolitis in the Treatment of Solid Tumors: A Case Report and Review of the Literature.
Case Rep Oncol. 2020 Apr 22;13(1):442-448. doi: 10.1159/000506896. eCollection 2020 Jan-Apr.
6
Pneumonitis and pulmonary fibrosis in a patient receiving adjuvant docetaxel and cyclophosphamide for stage 3 breast cancer: a case report and literature review.
J Med Case Rep. 2012 Nov 30;6:413. doi: 10.1186/1752-1947-6-413.
7
Successful conservative treatment of neutropenic enterocolitis complicating taxane-based chemotherapy: a report of five cases.
Am J Clin Oncol. 2000 Jun;23(3):309-13. doi: 10.1097/00000421-200006000-00021.
8
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9.
9
Permanent hair loss associated with taxane chemotherapy use in breast cancer: A retrospective survey at two tertiary UK cancer centres.
Eur J Cancer Care (Engl). 2021 May;30(3):e13395. doi: 10.1111/ecc.13395. Epub 2020 Dec 22.
10
Clostridium perfringens bacteraemia, an analysis of 28 cases over 10 years in a university hospital of Madrid.
Enferm Infecc Microbiol Clin (Engl Ed). 2018 Apr;36(4):225-228. doi: 10.1016/j.eimc.2017.02.002. Epub 2017 Apr 1.
引用本文的文献
1
Fatal febrile neutropenia during adjuvant chemotherapy for early breast cancer.
BMJ Case Rep. 2020 May 20;13(5):e233778. doi: 10.1136/bcr-2019-233778.
本文引用的文献
1
Comment on "impact of recent intravenous chemotherapy on outcome in severe sepsis and septic shock patients with haematological malignancies" by Vandijck et al.
Intensive Care Med. 2008 Oct;34(10):1929; author reply 1930-1. doi: 10.1007/s00134-008-1222-5. Epub 2008 Jul 18.
2
Phase I/II trial with docetaxel and S-1 for patients with advanced or recurrent gastric cancer with consideration to age.
Cancer Chemother Pharmacol. 2009 Feb;63(3):509-16. doi: 10.1007/s00280-008-0768-9. Epub 2008 May 15.
3
Hematopoietic growth factors: ESMO recommendations for the applications.
Ann Oncol. 2008 May;19 Suppl 2:ii116-8. doi: 10.1093/annonc/mdn107.
4
Delivery of adjuvant sequential dose-dense FEC-Doc to patients with breast cancer is feasible, but dose reductions and toxicity are dependent on treatment sequence.
Breast Cancer Res Treat. 2009 Mar;114(1):103-12. doi: 10.1007/s10549-008-9970-z. Epub 2008 Mar 16.
5
Phase III trial comparing doxorubicin plus cyclophosphamide with docetaxel plus cyclophosphamide as adjuvant therapy for operable breast cancer.
J Clin Oncol. 2006 Dec 1;24(34):5381-7. doi: 10.1200/JCO.2006.06.5391.
6
Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC PACS 01 Trial.
J Clin Oncol. 2006 Dec 20;24(36):5664-71. doi: 10.1200/JCO.2006.07.3916. Epub 2006 Nov 20.
7
Toxicity and health-related quality of life in breast cancer patients receiving adjuvant docetaxel, doxorubicin, cyclophosphamide (TAC) or 5-fluorouracil, doxorubicin and cyclophosphamide (FAC): impact of adding primary prophylactic granulocyte-colony stimulating factor to the TAC regimen.
Ann Oncol. 2006 Aug;17(8):1205-12. doi: 10.1093/annonc/mdl135. Epub 2006 Jun 9.
8
Incidence and clinical significance of anaerobic bacteraemia in cancer patients: a 6-year retrospective study.
Clin Microbiol Infect. 2005 Sep;11(9):724-9. doi: 10.1111/j.1469-0691.2005.01214.x.
9
Potential for improvement of docetaxel-based chemotherapy: a pharmacological review.
Br J Cancer. 2005 Jul 25;93(2):173-7. doi: 10.1038/sj.bjc.6602698.
10
Adjuvant docetaxel for node-positive breast cancer.
N Engl J Med. 2005 Jun 2;352(22):2302-13. doi: 10.1056/NEJMoa043681.
Zotero 插件